1.70
+11.84%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Autonomix Medical
From its filings with the US Securities and Exchange Commission
Autonomix Medical is based in The Woodlands, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AMIX. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 March 2026, it reported revenue of $0 and a net loss of $16.7m. At that date it held total assets of $7.6m and shareholders' equity of $5.9m.
We are a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Our platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (“RF”) ablation, enabling a “sense, treat, verify” approach intended to improve the precision and consistency of nerve-targeted therapies.
The technology we have developed consists of a catheter-based system incorporating a proprietary microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. By placing signal amplification and digitization at or near the point of detection, this approach is intended to reduce signal degradation and improve detection of neural activity compared to conventional systems. We believe this may enable more precise localization of target nerves and support targeted therapeutic intervention.
Our development efforts are focused on two core components: diagnostic sensing and therapeutic RF ablation. In preclinical studies, our sensing technology has demonstrated the ability to detect signals from specific nerve bundles prior to ablation and confirm signal termination following treatment. We are currently refining the design of our catheter to meet requirements for human use in the United States.
Quoted from its 10-K, filed 27 May 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 29 Jan 2024
- Employees
- 3
- Website
- autonomix.com ↗
- Head office
- 21 WATERWAY AVENUE, SUITE 300, THE WOODLANDS, TX, 77380
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Walter KlempExecutive Chairman of the Board, since 2022$325,658
- Mr. Bradley HauserPresident, Chief Executive Officer$1.7m
- Ms. Lori BissonExecutive Vice Chairman of the Board, since 2023$659,098
- Mr. Trent SmithChief Financial Officer$618,131
- Mr. Landy TothChief Technology Officer$313,158
- Mr. Robert SchwartzChief Medical Officer$381,111
- Dr. Christopher CapelliIndependent Director$56,250
- Mr. Jonathan FosterIndependent Director$68,750
- Mr. David RobinsIndependent Director$60,000
- Ms. Jenene ThomasInvestor Relations
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Autonomix catheter with microchip sensing array detects neural signals 1,000 times more sensitive
- Developing two-fold technology for pain management in one procedure
- Platform technology addresses dozens of indications including cardiology and chronic pain
Weaknesses
- Only 3 full-time employees for a medical device company
- IPO on 29 January 2024 with limited operational history
- Headquartered in The Woodlands, Texas with no major medical hub presence
Opportunities
- Pancreatic cancer and pancreatitis pain management market needs effective solutions
- Expanding platform technology to cardiology and renal denervation indications
- Growing demand for peripheral nervous system disease treatments in US market
Threats
- Medical device industry competition from established players
- Regulatory hurdles for new medical device approvals in US
- High R&D costs for developing new medical technologies
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.